AAMRI (AMRI) Enters License Agreement for CRISPR-Cas9 Gene Editing Technology
Tweet Send to a Friend
AMRI (NASDAQ: AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE